Lifitegrast Shows Long-Term Safety and Efficacy for Dry Eye Disease in 7-Year Analysis
A 7-year postmarketing analysis of lifitegrast ophthalmic solution 5% (Xiidra) confirms its favorable safety profile with no new safety signals identified across nearly 800,000 patient treatment years.
MIEBO Demonstrates Efficacy in Dry Eye Disease Treatment
MIEBO (perfluorohexyloctane ophthalmic solution) is FDA-approved for treating the signs and symptoms of dry eye disease (DED).